ContraVir recruits CRO ImageIQ for shingles trial

Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise. ContraVir's top prospect is FV-100, an oral nucleoside treatment designed to stamp out the varicella zoster virus and relieve shingles-associated pain. ImageIQ is on board to provide its imaging-enabled electronic data capture technology, helping investigators handle images of zoster rashes from the study's many sites to chart the drug's effect. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.